Several HER2 DNA/RNA aptamers have previously been developed and reported to target HER2 receptor in HER2+ BC with great specificity and selectivity, as summarised in Table 3 [8,9,27,28,46,116]. The gene discussed is ERBB2; the disease is breast cancer.